ARSHO SALAZAR: Open Payments
NPI 1194298109 · PASADENA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,459 in 174 payments from 16 companies in 2025. Trend: 2023 $3,607 · 2024 $4,443 · 2025 $5,459
Food & beverage: $5,350Education: $109
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 32 | $1,224 |
| Vanda Pharmaceuticals Inc. | 21 | $947 |
| Alkermes, Inc. | 22 | $555 |
| E.R. Squibb & Sons, L.L.C. | 21 | $544 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $443 |
| Neurocrine BioSciences, Inc. | 14 | $391 |
| Janssen Pharmaceuticals, Inc | 17 | $387 |
| Otsuka America Pharmaceutical, Inc. | 17 | $383 |
| Indivior Inc. | 5 | $136 |
| Braeburn Inc. | 1 | $119 |
Products named: UZEDY, HETLIOZ, COBENFY, ARISTADA, CAPLYTA, INGREZZA, INVEGA SUSTENNA, FANAPT.
Industry payments across CA — which companies pay providers there.
